Target, Home Depot,...
Health Care: Drugs
InterMune Inc. (ITMN: NASDAQ)
$9.99 -0.31 | -3.01%
05/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 9.99 |
| 52 Week High | 12.77 |
| 52 Week Low | 7.21 |
| Avg. Daily Vol. (Mil) | 1.34 |
| Beta (3 year) | 4.28 |
| Share Related Items | |
| Mkt Cap (Mil) | 815.38 |
| Shares Out (Mil) | 81.68 |
| Float (Mil) | 72.61 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 9.40 |
| Current Ratio | 9.70 |
| LT Debt/ Equity | 1.58 |
| Total Debt / Equity | 1.58 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 25.64 |
| Price/Book | 4.96 |
| Price/Cash Flow | -5.50 |
| Per Share Data | |
| Earnings | -2.25 |
| Sales | 0.39 |
| Book Value | 2.01 |
| Cash Flow | -1.82 |
| Business Summary | |
|---|---|
| InterMune, Inc. is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. | |
| General Information | |
| 3280 Bayshore Boulevrad
Brisbane, CA 94005 |
|
| www.intermune.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 282 | |
| CEO: Daniel G. Welch | |
| Short Interest | |
| Current Month (Mil) | 18.94 |
| Previous Month (Mil) | 18.37 |
| Short Interest Ratio (Days) | 12.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -30.60 |
| Return on Investments | -36.00 |
| Profitability | |
| Gross Margin | 81.20 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ITMN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserChopped Liver
- ContributorHot Biotech Stocks Traded b...
- ContributorMost-Searched Stocks for th...
- Userskyisfalling
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Contributor5 Biotech Stocks for 2012
- Contributor3 Health Care Stocks That C...
Latest ITMN Headlines from TheStreet
- ITMN Crosses Above Key Moving Average Level 04.29.13 | 04:04 pm
- J.P. Morgan Healthcare Confab Live Blog Day Three 01.09.13 | 10:01 am
- SAC's InterMune Trade Probe May Reveal Corrupted FDA Drug Review 12.10.12 | 02:12 pm
- 7 Stocks Under $10 Making Large Upside Moves 11.23.12 | 12:11 pm
- 4 Health Care Stocks Under $10 Spiking Higher 10.17.12 | 02:10 pm
- Market Preview: A Rally on Fumes 10.02.12 | 05:10 pm
- InterMune's CEO Discusses France's Economic Committee's (CEPS) Authorization Of Reimbursement Of Esbriet Conference (Transcript) 09.11.12 | 06:09 pm
- Analysts' Actions: HD SBUX MUR WAG CVS 08.15.12 | 09:08 am
- InterMune's CEO Discusses Q2 2012 Earnings - Earnings Call Transcript 07.23.12 | 02:07 pm
- Verizon, InterMune: Market Movers 07.23.12 | 12:07 pm
Press Releases for ITMN
- InterMune To Release First Quarter Financial Results On April 24 - PR Newswire 04.17.13 | 08:04 am
- Esbriet® (pirfenidone) Receives Positive Final Appraisal Determination From NICE For Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire 03.20.13 | 09:03 pm
- Sean P. Nolan Joins InterMune As Executive Vice President And Chief Business Officer - PR Newswire 02.14.13 | 04:02 pm
- InterMune To Release Fourth Quarter Financial Results On February 21 - PR Newswire 02.11.13 | 08:02 am
- InterMune Announces Pricing Of Concurrent Public Offerings Of $105,000,000 Principal Amount Of Convertible Senior Notes And 13,500,000 Shares Of Common Stock - PR Newswire 01.16.13 | 01:01 am
- InterMune Announces Proposed Concurrent Public Offerings Of Common Stock And Convertible Debt - PR Newswire 01.14.13 | 04:01 pm
- InterMune Reports Preliminary Fourth Quarter 2012 Esbriet® (pirfenidone) Revenue And Other Recent Business Highlights - PR Newswire 01.03.13 | 04:01 pm
- InterMune To Present At J. P. Morgan Healthcare Conference - PR Newswire 01.02.13 | 08:01 am
- InterMune To Release Third Quarter Financial Results On November 7 - PR Newswire 10.31.12 | 08:10 am
- Health Canada Approves Esbriet® As First Treatment For Fatal Lung Disease - PR Newswire 10.02.12 | 04:10 pm
Partner Headlines for ITMN
- Healthcare: Big pharma, big data - Financial Times 04.04.13 | 05:04 pm
- SAC signals further action after $614m deal - Financial Times 03.18.13 | 09:03 pm
- Four Biotech Stocks On The Clock - Seeking Alpha 02.19.13 | 09:02 am
- US authorities widen SAC Capital probe - Financial Times 02.13.13 | 10:02 pm
- 3 High Beta Liquid Small-Cap Biotechnology Stocks That Are Breaking Out - Seeking Alpha 09.17.12 | 09:09 am
- French Reimbursement for Esbriet - Analyst Blog - NASDAQ 09.13.12 | 09:09 pm
- Positive RECAP for ITMN's Esbriet - Analyst Blog - NASDAQ 09.04.12 | 07:09 pm
- InterMune Reports New Analyses from the RECAP Study of Esbriet at ERS - Benzinga 09.03.12 | 11:09 am
- InterMune Earnings Call NUGGETS: Patient Growth, Esbriet on the Path to Success - Wall St. Cheat Sheet 07.25.12 | 01:07 pm
- RadioShack SLIDES to Sell and 4 Anayst-Downgraded Shares - Wall St. Cheat Sheet 07.24.12 | 04:07 am
